MSC for Treatment of cGVHD After Allo-HSCT

• Status: Recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients with chronic graft-versus-host disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Collaborators: Peking University People's Hospital; Sun Yat-sen University; Xinqiao Hospital, Army Medical University
• Treatments: Cyclosporine; Cyclosporins; Glucocorticoids

Criteria

Inclusion Criteria:

• A patient age of 18-65 years

• Recipients of allogeneic hematopoietic stem cell transplantation Patients with moderate/ severe cGVHD without systemic treatment

• Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study

Exclusion Criteria:

• Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)

• Primary disease relapse

• Expected lifetime less than 3 months

• Patients with any conditions not suitable for the trial (investigators' decision)